Cargando…

Discordance of pathological thin melanoma thickness and T stage in SEER registry: impacts on clinical management and research directions

BACKGROUND: Ultrathin melanoma was previously demonstrated to have higher risk for melanoma-specific mortality using SEER database. However, these guideline-changing conclusions has been recently challenged by miscoding of thickness. This present study was performed to assess the prognosis of thin a...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Zhichao, Li, Haizhou, Liu, Xinyang, Bae, Jinhong, Huang, Xin, Gao, Yashan, Xu, Xiangwen, Guo, Jihan, Lu, Lin, Zan, Tao, Li, Qingfeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5716686/
https://www.ncbi.nlm.nih.gov/pubmed/29228646
http://dx.doi.org/10.18632/oncotarget.21980
_version_ 1783284000336379904
author Wang, Zhichao
Li, Haizhou
Liu, Xinyang
Bae, Jinhong
Huang, Xin
Gao, Yashan
Xu, Xiangwen
Guo, Jihan
Lu, Lin
Zan, Tao
Li, Qingfeng
author_facet Wang, Zhichao
Li, Haizhou
Liu, Xinyang
Bae, Jinhong
Huang, Xin
Gao, Yashan
Xu, Xiangwen
Guo, Jihan
Lu, Lin
Zan, Tao
Li, Qingfeng
author_sort Wang, Zhichao
collection PubMed
description BACKGROUND: Ultrathin melanoma was previously demonstrated to have higher risk for melanoma-specific mortality using SEER database. However, these guideline-changing conclusions has been recently challenged by miscoding of thickness. This present study was performed to assess the prognosis of thin and ultrathin melanoma using only surgically-treated, pathologically confirmed and after removal of discordant cases. METHODS: Melanoma patients from SEER database who were initially diagnosed with histologically confirmed and surgically treated melanoma from 1998 to 2012 were included. Subjects with discordance between T stage and tumor thickness were excluded. Kaplan-Meier curves, log-rank test and multivariate Cox proportional hazards regression models were used. RESULTS: 55,754 patients met the strict inclusion criteria, but 16 (0.02%) and 803 (1.4%) patients were removed due to T0 stage and discordance between T stage and thickness, respectively. Therefore, 54,935 patients entered the analyses, among which 52,751 were LN negative and 2,184 were LN positive. In either overall or LN-negative patients, a straightforward dose-effect relationship of larger thickness with increasing mortality was observed. In contrast, in LN positive patients, the T1 subgroup demonstrated a similar survival with tumors in T2 mm subgroup. Multivariable analysis revealed same pattern, and significant interaction between T stage and LN involvement was found. Further categorizing T1 melanoma into 10 equal 0.10 mm increments demonstrated an unexpected “N”-shaped pattern of mortality in overall and LN negative ultrathin melanoma but not in LN positive melanoma. CONCLUSIONS: No difference in mortality was observed in T1-3 tumors with LN involvement. External and independent validation studies are warranted.
format Online
Article
Text
id pubmed-5716686
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-57166862017-12-08 Discordance of pathological thin melanoma thickness and T stage in SEER registry: impacts on clinical management and research directions Wang, Zhichao Li, Haizhou Liu, Xinyang Bae, Jinhong Huang, Xin Gao, Yashan Xu, Xiangwen Guo, Jihan Lu, Lin Zan, Tao Li, Qingfeng Oncotarget Research Paper BACKGROUND: Ultrathin melanoma was previously demonstrated to have higher risk for melanoma-specific mortality using SEER database. However, these guideline-changing conclusions has been recently challenged by miscoding of thickness. This present study was performed to assess the prognosis of thin and ultrathin melanoma using only surgically-treated, pathologically confirmed and after removal of discordant cases. METHODS: Melanoma patients from SEER database who were initially diagnosed with histologically confirmed and surgically treated melanoma from 1998 to 2012 were included. Subjects with discordance between T stage and tumor thickness were excluded. Kaplan-Meier curves, log-rank test and multivariate Cox proportional hazards regression models were used. RESULTS: 55,754 patients met the strict inclusion criteria, but 16 (0.02%) and 803 (1.4%) patients were removed due to T0 stage and discordance between T stage and thickness, respectively. Therefore, 54,935 patients entered the analyses, among which 52,751 were LN negative and 2,184 were LN positive. In either overall or LN-negative patients, a straightforward dose-effect relationship of larger thickness with increasing mortality was observed. In contrast, in LN positive patients, the T1 subgroup demonstrated a similar survival with tumors in T2 mm subgroup. Multivariable analysis revealed same pattern, and significant interaction between T stage and LN involvement was found. Further categorizing T1 melanoma into 10 equal 0.10 mm increments demonstrated an unexpected “N”-shaped pattern of mortality in overall and LN negative ultrathin melanoma but not in LN positive melanoma. CONCLUSIONS: No difference in mortality was observed in T1-3 tumors with LN involvement. External and independent validation studies are warranted. Impact Journals LLC 2017-10-24 /pmc/articles/PMC5716686/ /pubmed/29228646 http://dx.doi.org/10.18632/oncotarget.21980 Text en Copyright: © 2017 Wang et al. http://creativecommons.org/licenses/by/3.0/ This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) (CC-BY), which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Research Paper
Wang, Zhichao
Li, Haizhou
Liu, Xinyang
Bae, Jinhong
Huang, Xin
Gao, Yashan
Xu, Xiangwen
Guo, Jihan
Lu, Lin
Zan, Tao
Li, Qingfeng
Discordance of pathological thin melanoma thickness and T stage in SEER registry: impacts on clinical management and research directions
title Discordance of pathological thin melanoma thickness and T stage in SEER registry: impacts on clinical management and research directions
title_full Discordance of pathological thin melanoma thickness and T stage in SEER registry: impacts on clinical management and research directions
title_fullStr Discordance of pathological thin melanoma thickness and T stage in SEER registry: impacts on clinical management and research directions
title_full_unstemmed Discordance of pathological thin melanoma thickness and T stage in SEER registry: impacts on clinical management and research directions
title_short Discordance of pathological thin melanoma thickness and T stage in SEER registry: impacts on clinical management and research directions
title_sort discordance of pathological thin melanoma thickness and t stage in seer registry: impacts on clinical management and research directions
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5716686/
https://www.ncbi.nlm.nih.gov/pubmed/29228646
http://dx.doi.org/10.18632/oncotarget.21980
work_keys_str_mv AT wangzhichao discordanceofpathologicalthinmelanomathicknessandtstageinseerregistryimpactsonclinicalmanagementandresearchdirections
AT lihaizhou discordanceofpathologicalthinmelanomathicknessandtstageinseerregistryimpactsonclinicalmanagementandresearchdirections
AT liuxinyang discordanceofpathologicalthinmelanomathicknessandtstageinseerregistryimpactsonclinicalmanagementandresearchdirections
AT baejinhong discordanceofpathologicalthinmelanomathicknessandtstageinseerregistryimpactsonclinicalmanagementandresearchdirections
AT huangxin discordanceofpathologicalthinmelanomathicknessandtstageinseerregistryimpactsonclinicalmanagementandresearchdirections
AT gaoyashan discordanceofpathologicalthinmelanomathicknessandtstageinseerregistryimpactsonclinicalmanagementandresearchdirections
AT xuxiangwen discordanceofpathologicalthinmelanomathicknessandtstageinseerregistryimpactsonclinicalmanagementandresearchdirections
AT guojihan discordanceofpathologicalthinmelanomathicknessandtstageinseerregistryimpactsonclinicalmanagementandresearchdirections
AT lulin discordanceofpathologicalthinmelanomathicknessandtstageinseerregistryimpactsonclinicalmanagementandresearchdirections
AT zantao discordanceofpathologicalthinmelanomathicknessandtstageinseerregistryimpactsonclinicalmanagementandresearchdirections
AT liqingfeng discordanceofpathologicalthinmelanomathicknessandtstageinseerregistryimpactsonclinicalmanagementandresearchdirections